Prot #21181: A Multicenter, Randomized, Prospective Double-Blind, Cross-Over Phase 3 Study to Evaluate the Efficacy and Safety of 0.04 mmol Gd/kg Body Weight of Gadoquatrane for MRI in Adults with Known or Suspected Pathology of the Central Nervous Syste

Project: Research project

Project Details

Effective start/end date1/19/241/19/27


  • Bayer HealthCare Pharmaceuticals, Inc. (Prot #21181)